These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27626976)

  • 21. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feminizing Adrenocortical Carcinoma: The Source of Estrogen Production and the Role of Adrenal-Gonadal Dedifferentiation.
    Wu L; Xie J; Jiang L; Su T; Ye L; Zhou W; Jiang Y; Zhang C; Ning G; Wang W
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3706-3713. PubMed ID: 30053001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
    Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
    Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
    Mariniello B; Rosato A; Zuccolotto G; Rubin B; Cicala MV; Finco I; Iacobone M; Frigo AC; Fassina A; Pezzani R; Mantero F
    Endocr Relat Cancer; 2012 Aug; 19(4):527-39. PubMed ID: 22673336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
    Salomon A; Keramidas M; Maisin C; Thomas M
    Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
    Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
    PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
    Chapman A; Durand J; Ouadi L; Bourdeau I
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines.
    Tamburello M; Abate A; Rossini E; Basnet RM; Zizioli D; Cosentini D; Hantel C; Laganà M; Tiberio GAM; Grisanti S; Memo M; Berruti A; Sigala S
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
    Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
    Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
    Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
    Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth.
    van Koetsveld PM; Vitale G; de Herder WW; Feelders RA; van der Wansem K; Waaijers M; van Eijck CH; Speel EJ; Croze E; van der Lely AJ; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4537-43. PubMed ID: 16912135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma.
    Huang J; Sun C; Zhang T; Pan L; Wang S; He Q; Li D
    Tumour Biol; 2014 Aug; 35(8):8193-9. PubMed ID: 24850175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.
    Kuai R; Subramanian C; White PT; Timmermann BN; Moon JJ; Cohen MS; Schwendeman A
    Int J Nanomedicine; 2017; 12():6581-6594. PubMed ID: 28919755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.